Koninklijke Philips/€PHIA

06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX

About Koninklijke Philips

Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.

Ticker

€PHIA
Sector

Primary listing

AEX

Employees

67,035

PHIA Metrics

BasicAdvanced
€24B
142.46
€0.18
0.91
€0.85
3.36%

What the Analysts think about PHIA

Analyst ratings (Buy, Hold, Sell) for Koninklijke Philips stock.

Bulls say / Bears say

Philips delivered a 12.4% adjusted EBITA margin in Q2 2025, a 130 basis point expansion year-over-year, indicating effective cost management and profitable growth outpacing tariff and currency headwinds. (Reuters)
Comparable order intake grew 6% in Q2 2025, reflecting strengthening demand for its AI-enabled diagnostic systems and image-guided therapy platforms, which should support sustained revenue momentum. (Reuters)
The company secured a long-term partnership with Indonesia’s Ministry of Health to deploy its Azurion image-guided therapy systems nationwide, opening access to care for over 280 million people and bolstering future revenue streams. (Reuters)
Philips faces an estimated €150–200 million tariff headwind for 2025 after the U.S.–EU deal, which could weigh on profitability despite recent margin improvements. (Reuters)
European investor group VEB has filed for a judicial inquiry into Philips over its 2021 sleep apnea device recall, alleging misleading disclosures and heightening legal and reputational risk. (Reuters)
The U.S. FDA issued a warning letter to three Philips facilities for violating manufacturing standards, labeling their products “adulterated” and prompting a near 5% drop in U.S.-listed shares. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.

PHIA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PHIA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €PHIA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs